Navigation Links
AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer's Vaccine
Date:7/16/2008

VIENNA, Austria, July 16 /PRNewswire/ -- In the clinical phase I trial AFF001, AFFiRiS GmbH has now recruited the 24 Alzheimer patients planned for this trial. The trial aims to investigate the tolerability and safety of an innovative Alzheimer's vaccine (AFFITOPE AD01). In the trial, all patients have now been vaccinated at least once and have so far tolerated the vaccine extremely well. The treatment provides for four vaccinations administered at monthly intervals and is due to be fully completed by this October. The vaccine's tolerability can then be conclusively evaluated. So far the results indicate good tolerability for this Alzheimer's vaccine from AFFiRiS GmbH. It is on this basis that recruitment of further patients has already begun for the clinical trial of a second Alzheimer's vaccine by AFFiRiS.

Vienna-based AFFiRiS GmbH has announced the successful completion of patient recruitment for clinical phase I testing of its Alzheimer's vaccine AD01. The vaccine is being administered at the Vienna General Hospital (AKH) to 24 Alzheimer's patients at a mild to moderate stage of the disease. The patients are being vaccinated a total of four times over a three-month period. During this time, and over a further two months, the safety and tolerability of the vaccine is being investigated. A professional care network with the highest medical standards ensures the patients' health and well-being.

Commenting on the planned progression of the trial, Dr. Walter Schmidt, CEO of AFFiRiS GmbH says: "We have now treated the maximum number of patients for the first time. After the end of the trial in a few months' time, we will know whether the impression so far of our vaccine's good tolerability is confirmed. As patient interest in the last few months has grown significantly, we are delighted that we are already in a position to offer participation in clinical testing of our second Alzheimer's vaccine, AFFITOPE AD02. The support from our largest investor, MIG-Fonds, is crucial in this regard, as only sound financing enables this rapid progression in clinical studies."

The Alzheimer's vaccines developed by AFFiRiS are based on AFFITOME technology developed in-house, which functions using the mimotope principle. This technology enables the development of customized vaccines known as AFFITOPE. Dr. Schmidt explains the special features of AFFiRiS's approach to the Alzheimer's vaccine: "Alzheimer's is caused by beta-amyloid, an unwanted fragment of one of the body's own proteins that occurs on the surface of brain cells. Development of a successful vaccine is extremely challenging as it is vital to ensure that antibodies only attack beta-amyloid if it occurs separated in the brain fluid but not as long as it is still part of the normal APP protein on the brain cells. The brain cells would otherwise be attacked. Thanks to AFFITOME technology, we are in the unique position of being able to safely protect the brain cells and only combat the disease-causing beta-amyloid."

AFFITOME technology patented by the company enables scientists to create both molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics. These strengths are now being used in developing the AD01 and AD02 vaccines, both of which align the immune system against the same beta-amyloid structure. However, AFFITOME technology can also be used to have a positive influence on other human rogue proteins - such as lipid metabolism enzymes. Consequently, an appropriate development by AFFiRiS could provide an effective treatment for atherosclerosis.

Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains his views on this development by AFFiRiS GmbH: "The company specialises in the development of treatments for diseases that urgently require a medical solution and also offer attractive market potential. With 22 million sufferers predicted for 2025 and no effective treatment, Alzheimer's is one such disease. The second disease that AFFiRiS has chosen to tackle is atherosclerosis, where a tailor-made vaccine is also under development. The company's development pipeline is already full, with the business model - which we support in full - envisaging a new product entering clinical testing every two years."

About AFFiRiS GmbH (as at July 2008):

AFFiRiS GmbH develops peptide-based vaccines for the treatment of Alzheimer's disease, atherosclerosis and other diseases that urgently require a medical solution. The company has established platform technologies and registered the corresponding patent families. The first patents have already been issued. The company employs 35 highly qualified members of staff on 600msquared of rented laboratory facilities at the Campus Vienna Biocenter (http://www.affiris.com).

About MIG-Fonds:

The participation of MIG Verwaltungs AG in AFFiRiS GmbH represents the continuation of a tried-and-tested approach. Investment is only made in selected companies in Germany and Austria after their viability has been thoroughly audited. Its innovative, high-potential products and the entrepreneurial skills of its management teams are both key. MIG Verwaltungs AG is supported by Alfred Wieder AG. This specialist in venture capital is experienced in the sale of holdings and is therefore the first point of contact for any potential investors.

Contact for AFFiRiS GmbH:

Dr. Walter Schmidt

Campus Vienna Biocenter 2

1030 Vienna

Austria

T +43-1-798-1575-10

E office@affiris.com

Copy Editing & Distribution

PR&D - Public Relations for Research & Education

Campus Vienna Biocenter 2

1030 Vienna

Austria

T +43-1-505-70-44

E contact@prd.at


'/>"/>
SOURCE AFFiRiS GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Callisto Reports on Second-Quarter 2007 Milestones
2. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
3. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
4. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
5. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
6. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
7. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
8. Medarex to Receive Milestone Payment from Amgen
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
11. Bionomics Achieves US$1 Million Milestone Payment from Genmab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , le 27 Avril 2016 ... a progressé de +5% sur le trimestre, soutenu ... de consommables  Croissance de +16% des ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; ... confocale laser, annonce aujourd,hui son chiffre d,affaires pour ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Shamangelic Healing, ... addition Onnit brand Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization ... optimization products to the store is just one more way Shamangelic Healing supports ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House announced efforts ... more information about their loan terms and accounts, and more protections for borrowers. ... federal and private loans, has reached $1.3 trillion, with 43 million Americans holding ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton Business ... Award, the Michelson People’s Choice Award, and the Committee Award for Most ‘Wow ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Robert Mondavi, one of the dentists ... dentistry is a fast-growing field as more patients are discovering the many different ways ... about the options currently available to them and which ones might work for their ...
(Date:4/29/2016)... Jupiter, FL (PRWEB) , ... April 29, 2016 ... ... it will feature Grassland Dairy Products, Inc. in an upcoming episode, airing third ... than a century of churning cream into butter, Grassland Dairy Products, located in ...
Breaking Medicine News(10 mins):